Duration and reliability of the silent period in individuals with spinal cord injury

Hannah Sfreddo[a]*, Jaclyn R. Wecht[a]*, Ola Alsalman[a,b], Yu-Kuang Wu [a,b], Noam Y. Harel [a,b]

* Contributed equally

[a], James J. Peters VA Medical Center, 130 West Kingsbridge Road, Bronx, New York 10468 USA

[b], Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, New York 10029 USA

Corresponding Author:

Noam Y. Harel, MD, PhD

718-584-9000 x1742 (p); 888-299-1965 (f); noam.harel@mssm.edu

Objective: We aim to better understand the silent period (SP), an inhibitory counterpart to the well-known motor evoked potential (MEP) elicited by transcranial magnetic stimulation (TMS), in individuals with spinal cord injury (SCI).

Methods: Electromyographic responses were measured in the target abductor pollicis brevis at rest (TMS at 120% of resting motor threshold (RMT)) and during maximal effort (TMS at 110% of RMT). Participants with chronic cervical SCI (n=9) and able-bodied volunteers (n=12) underwent between 3-7 sessions of stimulation on separate days. The primary outcomes were the magnitude and reliability of SP duration, resting and active MEP amplitudes, and RMT.

Results: SCI participants showed significantly increased RMT, decreased MEP amplitudes, and non-significantly longer SP duration compared to AB participants. In contrast to high inter-participant variability, SP duration demonstrated reduced intra-participant variability within and across sessions compared with resting and active MEP amplitudes. SCI participants also demonstrated a higher prevalence of SP 'interruptions' compared to AB participants.

Conclusions: SP reflects a balance between corticospinal excitatory and inhibitory processes. SP duration is more reliable within and across multiple sessions than MEP amplitude.

Significance: The higher reliability of SP duration may make it a useful outcome measure for future trials of SCI interventions.

Highlights

1. We compared characteristics of the silent period between individuals with spinal cord injury and able-bodied volunteers.

2. Silent period duration was insignificantly longer in spinal cord injury individuals.

3. Silent period duration was found to be a more reliable within-subject metric than motor evoked potential amplitude.

Objective: We aim to better understand the silent period (SP), an inhibitory counterpart to the well-known motor evoked potential (MEP) elicited by transcranial magnetic stimulation (TMS), in individuals with spinal cord injury (SCI).

Methods: Electromyographic responses were measured in the target abductor pollicis brevis at rest (TMS at 120% of resting motor threshold (RMT)) and during maximal effort (TMS at 110% of RMT). Participants with chronic cervical SCI (n=9) and able-bodied volunteers (n=12) underwent between 3-7 sessions of stimulation on separate days. The primary outcomes were the magnitude and reliability of SP duration, resting and active MEP amplitudes, and RMT.

Results: SCI participants showed significantly increased RMT, decreased MEP amplitudes, and non-significantly longer SP duration compared to AB participants. In contrast to high inter-participant variability, SP duration demonstrated reduced intra-participant variability within and

across sessions compared with resting and active MEP amplitudes. SCI participants also demonstrated a higher prevalence of SP ‘interruptions’ compared to AB participants.

Conclusions: SP reflects a balance between corticospinal excitatory and inhibitory processes. SP duration is more reliable within and across multiple sessions than MEP amplitude.

Significance: The higher reliability of SP duration may make it a useful outcome measure for future trials of SCI interventions.

Keywords: Transcranial magnetic stimulation, motor evoked potential, silent period, spinal cord injury, reliability

1 Introduction

The motor evoked potential (MEP) amplitude in response to transcranial magnetic stimulation (TMS) is one of the most commonly used outcome measures for tracking neurophysiology of the corticospinal system. Spinal cord injury (SCI) reduces MEP amplitude in muscles below the injury, reflecting reduced excitatory transmission across the spinal lesion. In contrast, corticospinal inhibitory processes are comparatively understudied after SCI. The silent period (SP) occurs upon TMS administration to the contralateral motor cortex during volitional contraction of the target muscle. The resulting MEP is followed by a brief period of electromyographic (EMG) suppression (silent period) usually lasting 100-300 milliseconds [1–4] (Figure 1).

Spinal inhibitory mechanisms contribute to the first ~50 ms of the SP through segmental recurrent inhibition of motor neurons [1,3]. Intracortical gamma-aminobutyric acid $(GABA)_B$ receptors that mediate inhibitory feedback onto pyramidal motor cortex neurons play a major role in mediating the remainder of the SP [2,5]. This is most clearly demonstrated by the elongation of SP duration when baclofen, a specific $GABA_B$ receptor agonist, is delivered intrathecally [6,7]. However, studies of oral and intravenous baclofen have failed to demonstrate a significant effect on SP duration [5,8,9].

Lesions of the nervous system may lengthen or shorten SP duration. Cerebral pathologies that lengthen SP include stroke [10–12], epilepsy [13,14], and depression [15]. Conversely, pathologies that

shorten SP include unmedicated schizophrenia [16], bipolar disorder [17], and chronic neuropathic pain [18].

Few prior studies have investigated SP in the SCI population, with mixed results [8,19–22]. It is not yet fully elucidated whether SCI lengthens SP (perhaps due to decreased afferent feedback from the periphery onto cortical GABAergic interneurons) or shortens SP (perhaps due to increased cortical or spinal segmental excitability). Furthermore, the relative reliability of SP duration as an outcome metric in SCI relative to the more commonly used MEP amplitude is hardly known [23]. Therefore, we compared magnitude and variability of hand muscle SP durations, MEP thresholds, and MEP amplitudes in individuals with chronic cervical SCI and able-bodied volunteers across multiple testing sessions.

2 Methods

2.1 Design – This experiment was an exploratory portion of a larger study in which we tested a novel configuration for non-invasive cervical transcutaneous spinal stimulation (clinicaltrials.gov NCT02469675) [24]. All procedures were approved by the Institutional Review Board of the James J. Peters VA Medical Center, Bronx, NY. All applicable institutional and governmental regulations concerning the ethical participation of human volunteers were followed during this research.

2.3 General Procedure – Neurological examination was performed according to the International Standards for the Neurological Classification of Spinal Cord Injury (ISNCSCI). Sessions were performed on separate days at a consistent time of day per participant, with attempts to maintain consistent quantity and timing of caffeine intake. Stimulation was delivered with participants in a seated upright position in an adjustable TMS treatment chair (Magventure), or for one participant, in her own wheelchair. For participants without neurological injury, TMS was targeted toward the dominant hand. For those with SCI, TMS was targeted toward the hand with lower motor thresholds and more reliable electrophysiological responses. Arms and hands were pronated and relaxed on a cushion placed in the participant's lap.

2.4 Transcranial Magnetic Stimulation (TMS) – A MagPro R30 or X100 system (Magventure) with 80mm winged coil (D-B80) was used. The magnet was oriented at a 45-degree angle from the sagittal plane, centered over the hand motor cortex hotspot for maximal APB response. The first 11 participants wore reusable cloth headcaps upon which the hotspot was labeled with a marker in relation to the vertex. Our laboratory obtained an optical infrared tracking system (Northern Digital Polaris) integrated with a Brainsight neural navigation system (Rogue Research) that was used to track hotspots from participant 12 and onward. RMT was determined as the percent of maximal stimulator output required to elicit an MEP in the APB muscle of at least 50 μV in 5 out of 10 repetitions.

2.5 Electromyographic Data – EMG of the target APB was recorded using surface sensors with 300x preamplification, 15-2,000 Hz bandwidth, and internal grounding (Motion Lab Systems

Z03-002). EMG was collected at a sample rate of 5,000 Hz via digital acquisition board and customized LabVIEW software (National Instruments USB-6363). All EMG data were acquired and quantified using custom LabVIEW scripts.

2.6 Eliciting and Measuring the Silent Period (SP) – While participants pinched a dynamometer between their thumb and third finger using maximal effort, a single TMS pulse was delivered over the hand motor cortex hotspot at 110% of each participant's RMT. The resulting MEP amplitude and SP duration in the contralateral APB muscle were measured. Five to six replicates were performed per session. Participants completed a total of 7 sessions on different days involving SP, apart from three individuals who withdrew from the study before completion.

To quantify SP_{DUR}, SP onset was visually defined as the end of the TMS-induced MEP, and SP offset was defined as the earliest resumption of pre-TMS EMG activity [25,26] (Figure 1).

We defined an "SP interruption" as a spike in EMG activity surrounded by SP silence, where the duration of interruption was less than 20 ms, and the absolute amplitude from one peak to the adjacent trough was at least 25% of the largest amplitude found during the 100 ms preceding the TMS impulse.

2.7 Analysis – Outcomes: The primary dependent variables were MEP amplitude (mV) at rest (MEP_{REST}) and during SP elicitation (MEP_{ACTIVE}), SP duration (ms) (SP_{DUR}), and RMT (% maximum stimulator output). SP interruptions were an exploratory outcome. For each participant, within-session means were computed from the 5-6 replicates of each test, then

averaged across sessions. Before group comparisons, each outcome was first tested for normality using the Shapiro-Wilks test. Normally distributed values (MEP_{ACTIVE}, SP_{DUR}, and RMT) were compared between AB and SCI groups using independent-sample t-tests. Non-normally distributed values (MEP_{REST}) were compared using an independent-samples Mann-Whitney U test.

Correlations: Bivariate correlations were assessed between the primary dependent variables (MEP_{REST}, MEP_{ACTIVE}, SP_{DUR}, and RMT) for each group. Pearson correlations were applied for normally distributed values, whereas Spearman's rho test was applied for non-normally distributed values.

Variability: Within-session coefficients of variation (CV) were computed for each participant from the 5-6 replicates of each test, then averaged across sessions. Note that RMT was only determined once per session, so it was not possible to determine within-session RMT variability. Between-session CVs were computed from the session means of each test. CVs were then averaged across participants within each group. As CV values were not normally distributed, the non-parametric related-samples Friedman's two-way analysis of variance by ranks test was applied to compare CVs across outcomes within each group. Significant values on Friedman's test were analyzed post-hoc between pairs of outcomes using related-samples Wilcoxon signed rank tests.

Interruptions: A chi-squared test was used to compare the frequency of participants with interrupted SPs between groups. As interruption values were not normally distributed, the non-

parametric Mann-Whitney U test was used to compare number of interruptions per participant between groups.

Excel (Microsoft) and SPSS Version 25 (IBM) were used for all analyses.

Individual-level data is included as Supplementary Data 1 (by participant, averaged across sessions) and Supplementary Data 2 (by participant per session).

3 Results

3.1 Participants – 21 individuals (12 AB and 9 SCI; 17 males, 4 females) participated in this study (Table 1). Participants ranged in age from 22 to 64 years old. Of the 9 SCI participants, eight had traumatic SCI, one had idiopathic transverse myelitis.

Table 1A – SCI Demographics

ID	Gender	Age	Etiology of Injury	DOI (Years)	LOI	ISNCSCI Grade	TMS Threshold (% MSO)
1	M	29	T	3	C8	C	45.9
2	M	52	T	17	C8	C	35.8

18	M	64	T	14	C4	D	59.4
23	M	57	T	12	C4	D	60.8
27	M	40	T	14	C4	D	69.7
28	M	42	T	16	C5	D	65.9
31	M	54	T	6	C5	C	52.7
34	F	52	T	16	C4	B	72.0
39	F	22	NT	1	C5	C	30.0
Totals	**7M, 2F**	**45.8 (22-64)**	**8T, 1NT**	**11 (1-17)**	**C4-C8**	**1B, 4C, 4D**	**54.7 (30.0-72.0)**

Table 1B – AB Demographics

ID	Gender	Age	TMS Threshold (% MSO)
5	M	25	35.1
8	M	27	34.1
9	M	44	35.9
11	F	22	38.2
12	F	23	30.6
14	M	44	32.6
15	M	45	44.4
16	M	24	52.3

22	M	58	53.9
25	M	55	41.9
36	M	23	32.6
38	M	22	53.0
Totals	**10M, 2F**	**34.3 (22-58)**	**40.4 (30.6-53.9)**

Table 1. Participant demographics. A) SCI. Etiology of Injury – traumatic (T) or not traumatic (NT); DOI – duration of injury; LOI – neurological level of injury; ISNCSCI – International Standards for the Neurological Classification of SCI; %MSO – percent of maximal stimulator output. **B) AB**.

3.2 SP duration – SCI participants showed non-significantly longer SPs (111.40 ± 18.39 ms; range 46.90 – 216.17 ms) than AB participants (97.99 ± 9.88 ms; range 35.30 – 152.86 ms) (non-significant, independent-sample t-test) (Table 2).

3.3 Resting motor threshold – SCI participants showed significantly higher RMTs (54.69 ± 4.94% maximum stimulator output; range 30.0 – 72.0) than AB participants (40.37 ± 2.48% maximum stimulator output, range 30.6 – 53.9) ($p=0.012$, independent-sample t-test) (Table 2).

3.4 MEP amplitudes – SCI participants showed significantly lower MEP_{REST} amplitudes (0.148 ± 0.018 mV) than AB participants (0.462 ± 0.094 mV) ($p<0.0005$ independent-samples Mann-Whitney U test). SCI participants showed significantly lower MEP_{ACTIVE} amplitudes (0.700 ± 0.133 mV) than AB participants (2.305 ± 0.233 mV) ($p<0.0005$ independent-sample t-test) (Table 2).

Table 2

Outcome	AB (n=12)	SCI (n=9)
RMT (% MSO) *	**40.37** (2.48)	**54.69** (4.94)
SP_{DUR} (ms)	**97.99** (9.88)	**111.4** (18.39)
MEP_{REST} (mV)*	**0.462** (0.094)	**0.148** (0.018)
MEP_{ACTIVE} (mV) *	**2.305** (0.233)	**0.700** (0.133)

Table 2 – Between-group comparisons. Means across sessions (S.E.M.). RMT, resting motor threshold. % MSO, percent maximum stimulator output. SP_{DUR}, SP duration. ms, milliseconds. MEP_{REST}, amplitude of resting motor evoked potential. mV, millivolts. MEP_{ACTIVE}, amplitude of active motor evoked potential. *, statistically significant between-group difference.

3.5 Correlations – In AB participants, SP duration was inversely correlated with MEP_{REST} amplitudes (Spearman's rho -0.790, p=0.002), with a tendency toward inverse correlation with MEP_{ACTIVE} amplitudes (Pearson correlation -0.547, p=0.065). In SCI participants, SP duration was not significantly correlated with MEP amplitudes (Pearson correlation 0.072 for MEP_{REST} amplitude, -0.202 for MEP_{ACTIVE} amplitude).

3.6 Intraindividual variability within sessions (Table 3, Figure 2A) – In AB volunteers, the within-session CV was 13.05 ± 1.40 for SP_{DUR}, 59.79 ± 4.49 for MEP_{REST}, and 21.83 ± 1.78 for

MEP_{ACTIVE} ($p<0.0005$ on related-samples Friedman's two-way analysis of variance by ranks test). Post hoc pairwise comparisons showed that SP_{DUR} had significantly lower within-session CV than both MEP_{REST} ($p=0.002$ on related-samples Wilcoxon signed rank test) and MEP_{ACTIVE} ($p=0.005$ on related-samples Wilcoxon signed rank test). In SCI participants, the CV was 16.08 ± 2.56 for SP_{DUR}, 52.93 ± 6.18 for MEP_{REST}, and 28.38 ± 2.64 for MEP_{ACTIVE} ($p<0.0005$ on related-samples Friedman's two-way analysis of variance by ranks test). Post hoc pairwise comparisons showed that SP_{DUR} had significantly lower within-session CV than both MEP_{REST} ($p=0.008$ on related-samples Wilcoxon signed rank test) and MEP_{ACTIVE} ($p=0.028$ on related-samples Wilcoxon signed rank test). Thus, SP_{DUR} has lower within-session variability than MEP amplitudes in both able-bodied and SCI individuals.

Table 3

Outcome	Group	Within-session	Between-session
RMT	**AB**		**6.96** (0.69)
	SCI		**9.19** (1.21)
SP_{DUR}	**AB**	**13.05** (1.40)	**19.61** (2.67) ‡
	SCI	**16.08** (2.56)	**28.50** (5.30) ‡
MEP_{REST}	**AB**	**59.79** (4.49) *	**52.04** (6.32) *‡

	SCI	**52.93** (6.18) *	**45.08** (6.90) ‡
MEP_{ACTIVE}	**AB**	**21.83** (1.78) *	**33.58** (4.12) *‡
	SCI	**28.38** (2.64) *	**35.06** (3.63) ‡

Table 3 – Outcome variability. Coefficients of variation (S.E.M.) for AB and SCI groups. *****, statistically significant difference between SP_{DUR} and other outcomes within each group. ‡, statistically significant difference between RMT and other outcomes within each group.

3.7 Intraindividual variability across sessions (Table 3, Figure 2B) – In AB volunteers, the between-session CV was 19.61 ± 2.67 for SP_{DUR}, 52.04 ± 6.32 for MEP_{REST}, 33.58 ± 4.12 for MEP_{ACTIVE}, and 6.96 ± 0.69 for RMT ($p<0.0005$ on related-samples Friedman's two-way analysis of variance by ranks test). Post hoc pairwise comparisons showed that SP_{DUR} had significantly lower between-session CV than both MEP_{REST} ($p=0.002$ on related-samples Wilcoxon signed rank test) and MEP_{ACTIVE} ($p=0.019$ on related-samples Wilcoxon signed rank test), but significantly higher between-session CV than RMT ($p=0.004$ on related-samples Wilcoxon signed rank test). In SCI participants, the CV was 28.50 ± 5.30 for SP_{DUR}, 45.08 ± 6.90 for MEP_{REST}, 35.06 ± 3.63 for MEP_{ACTIVE}, and 9.19 ± 1.21 for RMT ($p<0.0005$ on related-samples Friedman's two-way analysis of variance by ranks test). Post hoc pairwise comparisons showed that SP_{DUR} had a non-significant trend toward lower between-session CV than MEP_{REST} ($p=0.086$ on related-samples Wilcoxon signed rank test), and no significant difference from MEP_{ACTIVE} ($p=0.314$ on related-samples Wilcoxon signed rank test). As in AB participants,

SP_{DUR} had significantly higher between-session CV than RMT (p=0.015 on related-samples Wilcoxon signed rank test) in SCI participants. Thus, SP_{DUR} had significantly lower between-session variability than MEP amplitudes in able-bodied but not SCI individuals. However, RMT values were clearly more reliable across sessions than SP duration or MEP amplitudes.

3.8 SP Interruptions – 3 out of 12 AB participants and 8 out of 9 SCI participants showed interrupted SPs (p =0.004; Pearson chi-square test). Per session, AB volunteers showed 0.089 ± 0.71 interruptions, while SCI volunteers showed 1.781 ± 0.787 interruptions (p=0.001 on independent-samples Mann-Whitney U test) (Figure 3). From the perspective of individual SP trials, there were five interrupted CSPs out of 467 total CSP events (1.07%) in AB participants, and 52 interrupted CSPs out of 242 total CSP events (21.5%) in SCI participants.

4 Discussion

The current study measured corticospinal excitatory-inhibitory balance as reflected by MEP amplitude and SP duration in individuals with and without SCI. Our data confirm the well-known finding that SCI individuals have higher TMS motor thresholds and lower MEP amplitudes than able-bodied volunteers, indicating reduced excitability of the motor cortex, reduced corticospinal transmission, reduced excitability of local spinal circuitry, or any combination thereof. Due to large variability *between* individuals, we found no significant difference in SP duration between SCI and able-bodied participants. Importantly, relative

variability *within* individuals of SP duration is lower than variability of MEP amplitude, suggesting that SP duration may be a useful outcome measure with higher signal-to-noise ratio.

Appropriate movement requires inhibitory neural feedback as well as neural excitation [27,28]. Consequently, imbalance between neural excitation and inhibition may contribute to the failure in restoration of useful motor function after SCI [29]. Whereas MEP amplitude represents a straightforward excitatory readout, the relationship between clinical symptoms, disease entities, and neurophysiological inhibitory pathways as reflected by SP duration is more complex. A prolonged SP has been reported in a number of cerebral pathologies such as stroke [10–12,] spinocerebellar ataxia [30], sport-related concussion [31], epilepsy [13,14], Huntington's disease [32], and depression [15]. On the other hand, shortened SP duration has been reported in unmedicated schizophrenia [16], bipolar disorder [17], obsessive compulsive disorder [33], writer's cramp [34], Parkinson's [35], Alzheimer's diseases [36], fibromyalgia [37], and chronic neuropathic pain [18].

Thus, lesions affecting the cortex, corticospinal tract, or segmental spinal circuits may affect SP duration in opposing fashion. Further complicating the interpretation of SP duration, a variety of experimental factors affect SP. In our study, we examined SP duration in the context of a maximal-effort pincer grip between the thumb and third finger, with a relatively low TMS intensity (110% of RMT). SP duration correlates positively with increases in TMS intensity, but does not correlate with level of volitional contraction [3,11,38,39]. SP duration is also highly task dependent. In young adults, the fractionated task of abducting the index finger demonstrated longer SP duration than a task involving pincer grip between the thumb and index finger, which demonstrated longer SP duration than a task involving power grip [40]. This suggests an inverse correlation between SP duration and the number of muscles used for a task. Another study in

healthy adults showed that increasing amounts of sensory afferent input shortened SP duration [41]. These studies demonstrated the importance of afferent feedback in downwardly modulating SP duration, presumably by inhibiting the cortical GABAergic interneurons that mediate SP [20]. Thus, SCI would be expected to prolong SP duration due to reduced afferent feedback through the lesioned cord.

Our study did not show a significant difference in SP duration between SCI and AB participants. We speculate that the relatively low TMS intensity used in our study contributed to shorter SP duration and increased variability between individuals, reducing sensitivity to detect differences [26,42]. Prior investigation of SP in the SCI population has been limited. In six participants after thoracolumbar SCI, SP duration in hand muscles above the lesion increased (APB muscle, “gentle” pincer effort; TMS intensity at 140-180% RMT), MEP amplitudes decreased, and cortical motor map representations shifted [19]. The altered cortical maps in this study, as well as the observed changes in muscles rostral to the spinal lesion level, suggested that these neurophysiological changes after SCI were cortical in origin.

Likewise, a study of 16 participants with chronic cervical SCI relative to 18 uninjured controls showed prolonged SP duration (FDI muscle, 25% effort, TMS intensity set to produce similar MEP amplitude across participants) after SCI, regardless of oral baclofen intake [8]. The difference in SP duration seen by Barry and colleagues was observed when evoked by TMS but not when evoked by transcranial electrical stimulation (TES) – since TMS activates corticospinal neurons indirectly through cortical interneurons, this discrepancy between TMS and TES pointed to cortical mechanisms for SP elongation after SCI. A study of nine males with chronic cervical SCI observed prolonged SP (extensor digitalis communis muscle, 10% effort, TMS

intensity at 110% AMT), increased motor thresholds, and shifted cortical maps relative to uninjured controls [21]. Participants with greater spinal cord atrophy in that study showed relatively greater changes in SP and motor thresholds, suggesting that corticospinal transmission and local cord circuitry contributed to the observed neurophysiological changes.

On the contrary, a study of three individuals with cervical SCI showed loss of SP in two of three hand muscles and all three foot muscles (50% effort, TMS intensity at 100% of stimulator output) [22]. The authors speculated that SP loss derived from abnormal ascending sensory activity leading to cortical hyperexcitability, and/or increased local spinal neuronal excitability.

Our findings of decreased coefficients of variation in SP duration relative to MEP amplitude support the contention that SP duration may be a more reliable TMS metric than MEP amplitude. One other study measured MEPs and SP across time in individuals with chronic incomplete tetraplegia [23]. In that study, SP duration had relatively high reliability for both stronger and weaker muscles, whereas MEP amplitude had medium reliability for stronger muscles and poor reliability for weaker muscles. Studies in able-bodied participants provide further evidence that SP duration is more reliable across sessions than across individuals [11,42]. Importantly, resting motor threshold, which is determined at the beginning of any experimental TMS session, showed the least between-session variability of the measures we examined. It remains to be determined whether motor threshold is more sensitive than other measures to detecting changes after interventions aimed to increase central neural transmission.

Our observation that SP duration in able-bodied participants tended to inversely correlate with MEP amplitude conflicts with the findings of Orth and Rothwell, who found a

strong positive correlation [42]. In that study, SP was determined in the FDI muscle at 20% effort across a range of TMS intensities, whereas our study assessed the APB muscle at maximal effort at low TMS intensity. Our observation that SP duration and MEP amplitude did not correlate in SCI participants suggests disruption of the delicate balance between excitatory and inhibitory pathways.

We observed an overwhelmingly higher prevalence of SP 'interruption' frequency in SCI relative to AB participants. The simplest explanation for these spikes in EMG activity within SPs is that these are fasciculations of individual motor units. Fasciculations represent spontaneous hyperexcitable discharges more often seen in individuals with lower motor neuron degeneration and injury, usually arising from the distal axons of lower motor neurons, and thus are less likely to be silenced by TMS [43,44]. Many individuals with chronic cervical SCI display frequent fasciculations in muscles innervated from the level of injury. Therefore, it is not surprising that SCI participants demonstrated a much higher SP interruption rate than AB participants.

Our study has several important limitations: The SCI group was older than the control group. Individuals in the SCI group were more likely to be taking oral baclofen or other neural inhibitory medications. However, oral baclofen has not clearly been shown to affect SP duration [45]. TMS intensity during SP measurements was at 110% of resting motor threshold – most studies have used higher TMS intensities, which is a key factor in longer SP duration and may reduce intersession variability [26]. Post hoc statistical analyses were not corrected for multiple comparisons.

Conclusion

In individuals with chronic cervical SCI relative to able-bodied controls, we confirmed the well-known findings that SCI individuals have higher TMS motor thresholds and lower TMS evoked potential amplitudes. We also observed non-significantly longer SP duration in SCI individuals. Importantly, we observed significantly lower within-person variability of SP duration than within-person variability of TMS response amplitude, suggesting that SP duration may be a useful outcome measure with higher signal-to-noise ratio. Ongoing studies in our lab will further correlate EMG with electroencephalographic features to shed more mechanistic insight into these phenomena.

CONFLICTS OF INTEREST

The investigators have no conflicts of interest to declare.

SOURCES OF FUNDING

New York State Department of Health C30599.

References

1. Fuhr P, Agostino R, Hallett M. Spinal motor neuron excitability during the silent period after cortical stimulation. Electroencephalogr Clin Neurophysiol Evoked Potentials. 1991;81(4):257–62.
2. Poston B, Kukke SN, Paine RW, Francis S, Hallett M. Cortical silent period duration and its implications for surround inhibition of a hand muscle. Eur J Neurosci. 2012 Oct;36(7):2964–71.
3. Inghilleri M, Berardelli A, Cruccu G, Manfredi M. Silent period evoked by transcranial stimulation of the human cortex and cervicomedullary junction. J Physiol [Internet]. 1993 Jul [cited 2018 Apr 15];466(1):521–34. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8410704
4. Wu L, Goto Y, Taniwaki T, Kinukawa N, Tobimatsu S. Different patterns of excitation and inhibition of the small hand and forearm muscles from magnetic brain stimulation in humans. Clin Neurophysiol. 2002;113(8):1286–94.
5. Inghilleri M, Berardelli A, Marchetti P, Manfredi M. Effects of diazepam, baclofen and thiopental on the silent period evoked by transcranial magnetic stimulation in humans. Exp Brain Res. 1996;109(3):467–72.
6. Siebner HR, Dressnandt J, Auer C, Conrad B. Continuous intrathecal baclofen infusions induced a marked increase of the transcranially evoked silent period in a patient with generalized dystonia. Muscle and Nerve. 1998 Sep;21(9):1209–12.
7. Stetkarova I, Kofler M. Differential effect of baclofen on cortical and spinal inhibitory

circuits. Clin Neurophysiol [Internet]. 2013 Feb [cited 2020 Apr 15];124(2):339–45. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22877625

8. Barry MD, Bunday KL, Chen R, Perez MA. Selective effects of baclofen on use-dependent modulation of GABAB inhibition after tetraplegia. J Neurosci [Internet]. 2013 Jul 31 [cited 2014 Aug 9];33(31):12898–907. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3728695&tool=pmcentrez&rendertype=abstract

9. McDonnell MN, Orekhov Y, Ziemann U. The role of GABAB receptors in intracortical inhibition in the human motor cortex. Exp Brain Res. 2006 Aug 18;173(1):86–93.

10. Braune HJ, Fritz C. Transcranial magnetic stimulation-evoked inhibition of voluntary muscle activity (silent period) is impaired in patients with ischemic hemispheric lesion. Stroke. 1995;26(4):550–3.

11. Kukowski B, Haug B. Quantitative evaluation of the silent period, evoked by transcranial magnetic stimulation during sustained muscle contraction, in normal man and in patients with stroke. Electromyogr Clin Neurophysiol. 1992;32(7–8):373–8.

12. Gray WA, Palmer JA, Wolf SL, Borich MR. Abnormal EEG Responses to TMS during the Cortical Silent Period Are Associated with Hand Function in Chronic Stroke. Neurorehabil Neural Repair. 2017;31(7):666–76.

13. Ertaş NK, Gül G, Altunhalka A, Kirbas D. Cortical silent period following transcranial magnetic stimulation in epileptic patients. Epileptic Disord [Internet]. 2000 Sep [cited 2020 Apr 3];2(3):137–40. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11022138

14. Macdonell RA, King MA, Newton MR, Curatolo JM, Reutens DC, Berkovic SF. Prolonged

cortical silent period after transcranial magnetic stimulation in generalized epilepsy. Neurology [Internet]. 2001 Aug 28 [cited 2020 May 17];57(4):706–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11524485

15. Steele JD, Glabus MF, Shajahan PM, Ebmeier KP. Increased cortical inhibition in depression: A prolonged silent period with transcranial magnetic stimulation (TMS). Psychol Med. 2000;30(3):565–70.

16. Daskalakis ZJ, Christensen BK, Chen R, Fitzgerald PB, Zipursky RB, Kapur S. Evidence for impaired cortical inhibition in schizophrenia using transcranial magnetic stimulation. Arch Gen Psychiatry. 2002;59(4):347–54.

17. Levinson AJ, Young LT, Fitzgerald PB, Daskalakis ZJ. Cortical inhibitory dysfunction in bipolar disorder: A study using transcranial magnetic stimulation. J Clin Psychopharmacol. 2007 Oct;27(5):493–7.

18. Lefaucheur JP, Drouot X, Ménard-Lefaucheur I, Keravel Y, Nguyen JP. Motor cortex rTMS restores defective intracortical inhibition in chronic neuropathic pain. Neurology. 2006 Nov;67(9):1568–74.

19. Lotze M, Laubis-Herrmann U, Topka H. Combination of TMS and fMRI reveals a specific pattern of reorganization in M1 in patients after complete spinal cord injury. Restor Neurol Neurosci [Internet]. 2006/05/25. 2006;24(2):97–107. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16720945

20. Nardone R, Golaszewski S, Bergmann J, Venturi A, Prünster I, Bratti A, et al. Motor cortex excitability changes following a lesion in the posterior columns of the cervical

spinal cord. Neurosci Lett. 2008 Mar 21;434(1):119–23.

21. Freund P, Rothwell JC, Craggs M, Thompson AJ, Bestmann S. Corticomotor representation to a human forearm muscle changes following cervical spinal cord injury. Eur J Neurosci [Internet]. 2011;34:1–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22082003

22. Shimizu T, Hino T, Komori T, Hirai S. Loss of the muscle silent period evoked by transcranial magnetic stimulation of the motor cortex in patients with cervical cord lesions. Neurosci Lett. 2000 Jun 9;286(3):199–202.

23. Potter-Baker KA, Janini DP, Frost FS, Chabra P, Varnerin N, Cunningham DA, et al. Reliability of TMS metrics in patients with chronic incomplete spinal cord injury. Spinal Cord [Internet]. 2016 Apr 5 [cited 2016 Apr 10];54(11):980–90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27045553

24. Wu Y-K, Levine JM, Wecht JR, Maher MT, LiMonta JM, Saeed S, et al. Posteroanterior cervical transcutaneous spinal stimulation targets ventral and dorsal nerve roots. Clin Neurophysiol International Federation of Clinical Neurophysiology [Internet]. 2020 Dec 13 [cited 2019 Dec 31];131(2):451–60. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31887616

25. Ridding MC, Rothwell JC, Inzelberg R. Changes in excitability of motor cortical circuitry in patients with parkinson’s disease. Ann Neurol. 1995;37(2):181–8.

26. Damron LA, Dearth DJ, Hoffman RL, Clark BC. Quantification of the corticospinal silent period evoked via transcranial magnetic stimulation. J Neurosci Methods. 2008 Aug 15;173(1):121–8.

27. Azim E, Fink AJP, Jessell TM. Internal and external feedback circuits for skilled forelimb movement. Cold Spring Harb Symp Quant Biol. 2014;79:81–92.

28. Nichols TR. Distributed force feedback in the spinal cord and the regulation of limb mechanics. Vol. 119, Journal of Neurophysiology. American Physiological Society; 2018. p. 1186–200.

29. Davey NJ. Responses of thenar muscles to transcranial magnetic stimulation of the motor cortex in patients with incomplete spinal cord injury. J Neurol Neurosurg Psychiatry. 1998;65(1):80–7.

30. Teo JTH, Schneider SA, Cheeran BJ, Fernandez-del-Olmo M, Giunti P, Rothwell JC, et al. Prolonged cortical silent period but normal sensorimotor plasticity in spinocerebellar ataxia 6. Mov Disord. 2008 Feb 15;23(3):378–85.

31. Tremblay S, De Beaumont L, Lassonde M, Théoret H. Evidence for the specificity of intracortical inhibitory dysfunction in asymptomatic concussed athletes. J Neurotrauma. 2011 Apr 1;28(4):493–502.

32. Modugno N, Currà A, Giovannelli M, Priori A, Squitieri F, Ruggieri S, et al. The prolonged cortical silent period in patients with Huntington's disease. Clin Neurophysiol. 2001;112(8):1470–4.

33. Richter MA, De Jesus DR, Hoppenbrouwers S, Daigle M, Deluce J, Ravindran LN, et al. Evidence for cortical inhibitory and excitatory dysfunction in obsessive compulsive disorder. Neuropsychopharmacology. 2012 Apr;37(5):1144–51.

34. Tinazzi M, Farina S, Edwards M, Moretto G, Restivo D, Fiaschi A, et al. Task-specific impairment of motor cortical excitation and inhibition in patients with writer's cramp.

Neurosci Lett. 2005 Apr 11;378(1):55–8.

35. Nakashima K, Wang Y, Shimoda M, Sakuma K, Takahashi K. Shortened silent period produced by magnetic cortical stimulation in patients with Parkinson's disease. J Neurol Sci. 1995;130(2):209–14.

36. Alagona G, Bella R, Ferri R, Carnemolla A, Pappalardo A, Costanzo E, et al. Transcranial magnetic stimulation in Alzheimer disease: Motor cortex excitability and cognitive severity. Neurosci Lett. 2001 Nov 13;314(1–2):57–60.

37. Salerno A, Thomas E, Olive P, Blotman F, Picot MC, Georgesco M. Motor cortical dysfunction disclosed by single and double magnetic stimulation in patients with fibromyalgia. Clin Neurophysiol. 2000 Jun 1;111(6):994–1001.

38. Triggs WJ, Macdonell RAL, Cros D, Chiappa KH, Shahani BT, Day BJ. Motor inhibition and excitation are independent effects of magnetic cortical stimulation. Ann Neurol. 1992;32(3):345–51.

39. Kojima S, Onishi H, Sugawara K, Kirimoto H, Suzuki M, Tamaki H. Modulation of the cortical silent period elicited by single- and paired-pulse transcranial magnetic stimulation. BMC Neurosci. 2013 Apr 2;14.

40. Tinazzi M, Farina S, Tamburin S, Facchini S, Fiaschi A, Restivo D, et al. Task-dependent modulation of excitatory and inhibitory functions within the human primary motor cortex. Exp Brain Res [Internet]. 2003 May [cited 2020 Mar 22];150(2):222–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12677319

41. Hess A, Kunesch E, Classen J, Hoeppner J, Stefan K, Benecke R. Task-dependent modulation of inhibitory actions within the primary motor cortex. Exp Brain Res.

1999;124(3):321–30.

42. Orth M, Rothwell JC. The cortical silent period: Intrinsic variability and relation to the waveform of the transcranial magnetic stimulation pulse. Clin Neurophysiol [Internet]. 2004 May [cited 2020 Mar 28];115(5):1076–82. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15066533

43. Layzer RB. The origin of muscle fasciculations and cramps. Muscle Nerve [Internet]. 1994 Nov 1 [cited 2020 May 24];17(11):1243–9. Available from: http://doi.wiley.com/10.1002/mus.880171102

44. Grapperon AM, Attarian S. Disorders of motor neurons manifested by hyperactivity. Vol. 173, Revue Neurologique. Elsevier Masson SAS; 2017. p. 345–51.

45. Ziemann U, Reis J, Schwenkreis P, Rosanova M, Strafella A, Badawy R, et al. TMS and drugs revisited 2014. Vol. 126, Clinical Neurophysiology. Elsevier Ireland Ltd; 2015. p. 1847–68.

Legends

Figure 1 – Schematic and examples of silent period. A) TMS is delivered (red line) to the hand motor cortex while the participant performs a volitional isometric pinch with the contralateral hand. The resulting MEP (black arrow) is followed by an EMG silent period before the resumption of baseline volitional EMG activity. **B) Representative silent period in able-bodied volunteer. C) Representative silent period in SCI participant.** APB, abductor pollicis brevis.

Figure 2 – Outcome variability. A) Within-session coefficient of variation for each group. **B)** Between-session coefficient of variation for each group. Error bars represent S.E.M. *, significantly different from SP duration; ‡, significantly different from RMT.

Figure 3 – SP interruptions by group and participant. The average number of interruptions per session for each participant. Error bars represent S.D.

Supplementary Data 1 – Participant-level data averaged across sessions.

InterssNum, number of interruptions per session; CVSPdurIntra, intrasession coefficient of variation for SP_{DUR}; CVMEPrestIntra, intrasession coefficient of variation for MEP_{REST}; CVMEPactiveIntra, intrasession coefficient of variation for MEP_{ACTIVE}; CVRMTInter, intersession coefficient of variation for RMT; CVSPdurInter, intersession coefficient of variation for SP_{DUR};

CVMEPrestInter, intersession coefficient of variation for MEP_{REST}; CVMEPactiveInter, intersession coefficient of variation for MEP_{ACTIVE}.

Supplementary Data 2 – Participant-level data listed per session.


A
APB
sEMG
TMS
EMG Activity
EMG Silence (SP)
EMG Activity Resumes
B
Amplitude (mV)
Time (s)
C
Amplitude (mV)
Time (s)

A


AB (n=12)
SCI (n=9)
Coefficient of variation (%)
100
90
80
70
60
50
40
30
20
10
0
SP Duration
MEP Active
MEP Rest
Outcome measure

B


AB (n=12)
SCI (n=9)
Coefficient of variation (%)
100
90
80
70
60
50
40
30
20
10
0
RMT
SP Duration
MEP Active
MEP Rest
Outcome measure


Number of interruptions
0
1
2
3
4
5
6
7
5
8
9
11
12
14
15
16
22
25
36
38
1
2
18
23
27
28
31
34
39